Effects Of Eltrombopag On Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia

Trial Profile

Effects Of Eltrombopag On Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Thrombocytopenia; Wiskott-Aldrich syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jan 2017 Planned End Date changed from 1 Jun 2013 to 1 Jun 2020.
    • 31 Jan 2017 Planned primary completion date changed from 1 Jun 2013 to 1 May 2019.
    • 31 Jan 2017 Status changed from Recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top